GlassScriptPhysician profile
Thomas P Archer
NPI 1336102888
$10,316.87
in general payments reported to CMS, 2019-2025
30 companies · $5,803 in 2025
The $5,803 reported for 2025 was more than what 92% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $285 · 2020: $33.48 · 2021: $47.60 · 2022: $282 · 2023: $1,140 · 2024: $2,726 · 2025: $5,803.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,125 · Consulting Fee: $2,850 · Travel and Lodging: $1,694.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,125.12 |
| Consulting Fee | $2,850.00 |
| Travel and Lodging | $1,693.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $6,628.36 | 2023-2025 | Barostim Neo System |
| Abiomed | $572.86 | 2019-2025 | Impella, Abiraterone Acetate |
| Novartis Pharmaceuticals Corporation | $532.04 | 2023-2025 | |
| Impulse Dynamics (USA) INC. | $437.11 | 2022-2025 | Optimizer, Optimizer |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $371.64 | 2023-2025 | Lifevest |
| Pfizer INC. | $336.58 | 2023-2025 | |
| Abbott Laboratories | $279.55 | 2019-2025 | Cardiomems |
| Merck Sharp & Dohme LLC | $200.73 | 2023-2024 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $124.18 | 2023-2025 | Camzyos, Eliquis |
| Amgen INC. | $99.67 | 2023-2025 | Repatha, Repatha |
| Regeneron Healthcare Solutions, INC. | $89.91 | 2024-2025 | Evkeeza |
| Alnylam Pharmaceuticals INC. | $77.29 | 2022-2025 | Onpattro, Amvuttra |
| Edwards Lifesciences Corporation | $76.27 | 2022 | |
| Bridgebio Pharma, INC. | $58.37 | 2025 | Attruby |
| Lexicon Pharmaceuticals, INC. | $49.64 | 2023-2024 | Inpefa |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $49.49 | 2024 | Arcalyst |
| Kestra Medical Technology Services, INC. | $41.76 | 2023 | Assure Wcd |
| Endotronix, INC. | $31.36 | 2025 | Cordella Pulomonary Artery Pressure Sensor |
| Chiesi USA, INC. | $30.26 | 2023-2025 | Kengreal, Cleviprex, Juxtapid |
| Philips North America LLC | $27.50 | 2025 | Diagnostic Ecg Service |
| Astrazeneca Pharmaceuticals LP | $27.19 | 2023-2024 | Farxiga |
| Sanofi-Aventis U.S. LLC | $27.11 | 2024 | |
| Heartflow, INC. | $26.11 | 2025 | |
| Astellas Pharma US INC | $22.74 | 2021 | |
| Biosense Webster, INC. | $19.70 | 2025 | Nuvision Ice Catheter |
| Lantheus Medical Imaging, INC. | $19.33 | 2022 | |
| Scpharmaceuticals INC. | $17.17 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $15.33 | 2023 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.61 | 2023 | Jardiance |
| Kiniksa Pharmaceuticals, LTD. | $13.01 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Archer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.